Wikidata entity: Q422229
C₂₂H₂₆N₂O₄S (P274)
Quantities
| P4250 | defined daily dose | 0.24 |
| P2067 | mass | 414.161 |
| P3780 | active ingredient in | ... | Q47521487 (Tiadylt) | Tiadylt |
| P3780 | active ingredient in | ... | Q47521488 (Matzim) | Matzim |
| P3780 | active ingredient in | ... | Q48826006 (Diltzac) | Diltzac |
| P3780 | active ingredient in | ... | Q48826030 (Tiazac) | Tiazac |
| P3780 | active ingredient in | ... | Q48826310 (Taztia) | Taztia |
| P3780 | active ingredient in | ... | Q48826328 (Dilt) | Dilt |
| P3780 | active ingredient in | ... | Q48826449 (Cardizem) | Cardizem |
| P3780 | active ingredient in | ... | Q48828866 (Dilacor) | Dilacor |
| P3780 | active ingredient in | ... | Q48829292 (Cartia) | Cartia |
| P233 | canonical SMILES | String | CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC | ??? |
| P373 | Commons category | String | Diltiazem | ??? |
| P527 | has part(s) | ... | Q627 (nitrogen) | nitrogen |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P527 | has part(s) | ... | Q682 (sulfur) | sulfur |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC | ??? |
| P8026 | LiverTox likelihood score | ... | Q83284310 (LiverTox toxicity likelihood category C) | LiverTox toxicity likelihood category C |
| P2175 | medical condition treated | ... | Q41861 (arterial hypertension) | arterial hypertension |
| P2175 | medical condition treated | ... | Q180762 (angina pectoris) | angina pectoris |
| P2175 | medical condition treated | ... | Q12152 (myocardial infarction) | myocardial infarction |
| P2175 | medical condition treated | ... | Q1598909 (supraventricular tachycardia) | supraventricular tachycardia |
| P2175 | medical condition treated | ... | Q815819 (atrial fibrillation) | atrial fibrillation |
| P129 | physically interacts with | ... | Q1499998 (Calcium voltage-gated channel subunit alpha1 C) | Calcium voltage-gated channel subunit alpha1 C |
| P129 | physically interacts with | ... | Q14905969 (Potassium voltage-gated channel, shaker-related subfamily, member 1) | Potassium voltage-gated channel, shaker-related subfamily, member 1 |
| P129 | physically interacts with | ... | Q21096394 (Potassium voltage-gated channel subfamily A member 5) | Potassium voltage-gated channel subfamily A member 5 |
| P129 | physically interacts with | ... | Q21108125 (5-hydroxytryptamine receptor 3A) | 5-hydroxytryptamine receptor 3A |
| P129 | physically interacts with | ... | Q21111803 (Calcium voltage-gated channel subunit alpha1 S) | Calcium voltage-gated channel subunit alpha1 S |
| P129 | physically interacts with | ... | Q21496563 (Potassium voltage gated channel, Shaw-related subfamily, member 1) | Potassium voltage gated channel, Shaw-related subfamily, member 1 |
| P129 | physically interacts with | ... | Q21496564 (Potassium voltage-gated channel, shaker-related subfamily, member 7) | Potassium voltage-gated channel, shaker-related subfamily, member 7 |
| P129 | physically interacts with | ... | Q21497936 (5-hydroxytryptamine (serotonin) receptor 3A) | 5-hydroxytryptamine (serotonin) receptor 3A |
| P129 | physically interacts with | ... | Q21984383 (Voltage-dependent L-type calcium channel subunit alpha-1F) | Voltage-dependent L-type calcium channel subunit alpha-1F |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P769 | significant drug interaction | ... | Q32089 (sirolimus) | sirolimus |
| P769 | significant drug interaction | ... | Q176533 (alfentanil) | alfentanil |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q58396 (imipramine) | imipramine |
| P769 | significant drug interaction | ... | Q174259 (droperidol) | droperidol |
| P769 | significant drug interaction | ... | Q367700 (cyclosporine) | cyclosporine |
| P769 | significant drug interaction | ... | Q408556 (levobunolol) | levobunolol |
| P769 | significant drug interaction | ... | Q409468 ((RS)-metoprolol) | (RS)-metoprolol |
| P769 | significant drug interaction | ... | Q213511 (erythromycin) | erythromycin |
| P769 | significant drug interaction | ... | Q411325 (atenolol) | atenolol |
| P769 | significant drug interaction | ... | Q412221 (clonidine) | clonidine |
| P769 | significant drug interaction | ... | Q412515 (bisoprolol) | bisoprolol |
| P769 | significant drug interaction | ... | Q412534 (carvedilol) | carvedilol |
| P769 | significant drug interaction | ... | Q413581 (bromocriptine) | bromocriptine |
| P769 | significant drug interaction | ... | Q410061 (amiodarone) | amiodarone |
| P769 | significant drug interaction | ... | Q410400 (phenytoin) | phenytoin |
| P769 | significant drug interaction | ... | Q958087 (labetalol) | labetalol |
| P769 | significant drug interaction | ... | Q2736873 (alfuzosin) | alfuzosin |
| P769 | significant drug interaction | ... | Q2873270 (avanafil) | avanafil |
| P769 | significant drug interaction | ... | Q668093 (atorvastatin) | atorvastatin |
| P769 | significant drug interaction | ... | Q670131 (simvastatin) | simvastatin |
| P769 | significant drug interaction | ... | Q5186964 (crizotinib) | crizotinib |
| P769 | significant drug interaction | ... | Q5473363 (fosphenytoin) | fosphenytoin |
| P769 | significant drug interaction | ... | Q5613599 (guanfacine) | guanfacine |
| P769 | significant drug interaction | ... | Q413591 (sotalol) | sotalol |
| P769 | significant drug interaction | ... | Q418101 (pindolol) | pindolol |
| P769 | significant drug interaction | ... | Q418130 (nebivolol) | nebivolol |
| P769 | significant drug interaction | ... | Q794162 (betaxolol) | betaxolol |
| P769 | significant drug interaction | ... | Q418139 (esmolol) | esmolol |
| P769 | significant drug interaction | ... | Q418857 (acebutolol) | acebutolol |
| P769 | significant drug interaction | ... | Q420586 (celiprolol) | celiprolol |
| P769 | significant drug interaction | ... | Q421274 (dantrolene) | dantrolene |
| P769 | significant drug interaction | ... | Q422222 (digoxin) | digoxin |
| P769 | significant drug interaction | ... | Q422618 (ritonavir) | ritonavir |
| P769 | significant drug interaction | ... | Q423364 (propranolol) | propranolol |
| P769 | significant drug interaction | ... | Q424161 (vardenafil) | vardenafil |
| P769 | significant drug interaction | ... | Q424238 (domperidone) | domperidone |
| P769 | significant drug interaction | ... | Q424952 (nadolol) | nadolol |
| P769 | significant drug interaction | ... | Q425137 (fingolimod) | fingolimod |
| P769 | significant drug interaction | ... | Q425729 (ivabradine) | ivabradine |
| P3364 | stereoisomer of | ... | Q27079274 (L-(cis)-diltiazem) | L-(cis)-diltiazem |
| P9989 | stylized name | String | dilTIAZem | ??? |
| P279 | subclass of | ... | Q193430 (heterocyclic compound) | heterocyclic compound |
| P279 | subclass of | ... | Q421700 (calcium channel blocker) | calcium channel blocker |
| P2868 | subject has role | ... | Q4008956 (vasodilator agent) | vasodilator agent |
| P2868 | subject has role | ... | Q50429907 (cardiovascular agent) | cardiovascular agent |
| P2868 | subject has role | ... | Q421700 (calcium channel blocker) | calcium channel blocker |
| P2868 | subject has role | ... | Q575890 (antihypertensive drug) | antihypertensive drug |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | diltiazem | ??? |
Why not click here or view trends?
log id: 2855573